Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

11.18
Delayed Data
As of Mar 29
 +0.50 / +4.68%
Today’s Change
10.35
Today|||52-Week Range
38.50
-23.00%
Year-to-Date
Silver Point Capital L.P. Buys Basic Energy Services, Key Energy Services, Penn Virgi...
Mar 29 / GuruFocus News - Paid Partner Content
Orexigen Inks Commercialization Deal for Contrave, Stock Up
Mar 28 / Zacks.com - Paid Partner Content
Valeant's Banks Extend a Lifeline
Mar 29 / TheStreet.com - Paid Partner Content
Former Valeant CEO Files Suit Against the Company
Mar 28 / TheStreet.com - Paid Partner Content
Saba Capital Management, L.P. Buys Allergan PLC, Alpine Total Dynamic Dividend Fund, ...
Mar 29 / GuruFocus News - Paid Partner Content
Can This Pharma Stock Withstand the 'Trump Effect'?
Mar 25 / TheStreet.com - Paid Partner Content
Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?
Mar 29 / Zacks.com - Paid Partner Content
Bill Ackman Finally Pukes: Beware of False Narratives
Mar 25 / GuruFocus News - Paid Partner Content
Behind the Bill Ackman Controversies
Mar 28 / GuruFocus News - Paid Partner Content
Francis Chou Comments on Valeant
Mar 24 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close10.68
Today’s open10.68
Day’s range10.67 - 11.43
Volume26,944,434
Average volume (3 months)17,888,999
Market cap$3.6B
Dividend yield--
Data as of 4:00pm ET, 03/29/2017

Growth & Valuation

Earnings growth (last year)-716.47%
Earnings growth (this year)-28.43%
Earnings growth (next 5 years)+3.95%
Revenue growth (last year)-7.39%
P/E ratioNM
Price/Sales0.52
Price/Book1.18

Competitors

 Today’s
change
Today’s
% change
MDCOMedicines Co-0.99-1.94%
CTLTCatalent Inc+0.10+0.35%
PTHNPatheon NV+0.01+0.04%
GLPGGalapagos NV+1.23+1.45%
Data as of 4:02pm ET, 03/29/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)$0.92
Annual revenue (last year)$9.7B
Annual profit (last year)-$2.4B
Net profit margin-24.90%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Qubec

Forecasts


Search for Jobs